The genetic programming that causes embryonic cells to differentiate into lung cells was described for the first time in a…
Articles by Marisa Wexler, MS
Enrollment is nearing completion for two Phase 2 clinical trials testing the experimental treatment ELX-02 in people with…
The Cystic Fibrosis (CF) Foundation awarded a nearly $700,000 contract to Calibr, the drug discovery and development arm…
The European Commission has approved a label extension for Kalydeco (ivacaftor), allowing the therapy to be used in…
The Regional Pharmaceutical Procurement Service in Northern Ireland and the National Health Service (NHS) Wales have reached an agreement with…
The Cystic Fibrosis Foundation (CFF) is celebrating the United States Food and Drug Administration’s decision to approve Trikafta. The therapy…
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a…
John Pirozzi, a representative of Chelsea Financial Services, will participate in the TCS New York City Marathon to…
The U.S. Food and Drug Administration (FDA) has designated Vast Therapeutics’ BIOC11 a Qualified Infectious Disease Product (QIDP) for…
Care for cystic fibrosis (CF) has improved substantially in recent decades, but there are still challenges ahead, particularly in ensuring…